Day: February 28, 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses. The private placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions. The financing includes...

Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024 HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today announced that it has closed a private placement to healthcare-focused institutional investors (“the investors”), including a life sciences-focused institutional investor, Samsara BioCapital, LLC (“Samsara”) and the JDRF T1D Fund, of (i) 464,377 shares of common stock at a price of $11.81 per share, which is the 45 day VWAP ended on January 29, 2024, and (ii) pre-funded warrants for 3,853,997 shares of common stock in lieu of vTv common stock in a private...

NAPLES, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology solutions for patients and providers, is thrilled to announce the addition of Garrett Gardi to its Advisory Board. With over two decades of experience in employee benefit plans, specializing in predictive cost analytics, consumer-driven platforms, and self-funded/alternative funding methodologies, Garrett brings a wealth of knowledge and expertise to the HealthLynked team. As HealthLynked embarks on a new phase of growth, focusing on engaging with large employers and payors to offer its innovative technology solutions to a broader audience, Garrett’s strategic guidance will be invaluable. His proven track record in designing effective employee benefit programs that take a proactive approach to...

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform”, said Sujal Patel, CEO of Nautilus. “We are building a groundbreaking, ‘first-in-the-world’ platform designed to unlock significant breakthroughs in biological research. Doing so requires that a number of meaningful innovations across each element of our platform – consumables, instrument, and software – weave together seamlessly. We continue...

SAN MATEO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) — Freshworks Inc., (NASDAQ: FRSH) today announced participation in the following events:JMP Securities Technology Conference: Tyler Sloat, Chief Financial Officer, is scheduled to participate in a fireside chat on Tuesday, March 5, 2024 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Morgan Stanley Technology, Media and Telecom Conference: Dennis Woodside, President, is scheduled to participate in a fireside chat on Wednesday, March 6, 2024 at 8:45 a.m. Pacific Time (11:45 a.m. Eastern Time)An audio webcast replay will be accessible from the Freshworks investor relations website at https://ir.freshworks.com. About Freshworks Inc.Freshworks Inc., (NASDAQ: FRSH) creates AI-boosted business software anyone can use. Purpose-built for IT, customer support, and sales and marketing...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:TD Cowen 44th Annual Healthcare Conference: Keith Gottesdiener, M.D., President and Chief Executive Officer, will participate in a panel discussion, “Emerging Genetic Therapy Approaches,” on Wednesday, March 6, 2024, at 12:50 p.m. ET in Boston, MA. Jefferies Biotech on the Bay Summit: Company management will host 1×1 investor meetings on Tuesday, March 12, 2024, in Miami Beach, FL.A live audio webcast of the panel discussion at the TD Cowen 44th Annual Healthcare Conference will be available under “Events & Presentations” in the News...

DALLAS, Feb. 28, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to participate in the following investor conferences:KeyBanc Capital Markets Emerging Technology SummitWednesday, March 6, 2024Fireside Chat at 2:00 pm ET / 11:00 am PTSan Francisco, CA36th Annual ROTH ConferenceMonday, March 18 and Tuesday, March 19, 2024Dana Point, CAKeyBanc Capital Markets Life Sciences & MedTech Investor Forum Wednesday, March 20, 2024Fireside Chat at 3:45 pm ET / 12:45 pm PTVirtualManagement will be hosting 1×1 meetings during these conferences. Interested parties may access live and archived webcasts of...

— On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 — — Plan to initiate TANDEM, pivotal Phase 3 trial evaluating obicetrapib and ezetimibe fixed-dose combination, in 1Q 2024; topline data expected in 1Q 2025 — — Expect to complete enrollment in Phase 3 PREVAIL CVOT in 1Q 2024; topline data expected in 2026 — — Completed $202 million upsized public offering, expanding shareholder base with strong participation from new investors, existing shareholders, and insiders; proforma cash of $500 million– NAARDEN, The Netherlands and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing...

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company’s investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity. “We are pleased to welcome Dominic to the Corbus team and look...

Kratos’ Head of Advanced Technology is recognized for his leadership in advancing interoperability in the satellite industry SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, is pleased to congratulate Stuart Daughtridge, Kratos VP of Advanced Technology, on being named a finalist for Via Satellite’s 2023 Satellite Executive of the Year Award. Nominees are chosen based on their contributions to the global satellite markets, technologies, business practices, services, innovations, advocacy or any combination thereof. Stuart is recognized for his role as Chairman and Director of the Digital Intermediate Frequency Interoperability Consortium (DIFI), an independent group dedicated to supporting interoperability...